The DOI matches its Crossref record.
Pharmacologic Factors Associated With Transient Neonatal Symptoms Following Prenatal Psychotropic Medication Exposure
Abstract
BACKGROUND: Selective serotonin reuptake inhibitor antidepressants (SSRIs) and benzodiazepines are frequently used to treat maternal depression and anxiety disorders during pregnancy. Recent reports suggest that prenatal SSRI exposure is associated with a neonatal discontinuation syndrome. It remains unclear whether these symptoms are directly related to SSRI exposure alone or are due to concurrent pharmacologic factors. Also, this study explores relationships between neonatal outcomes and medication levels during pregnancy, at delivery, and in the newborn period. METHOD: This study sought to compare newborn behavior following second and third trimester exposure to either single-agent SSRIs (group 1) or SSRIs combined with clonazepam (group 2). A prospective cohort of mothers and their infants (N = 46) who had received SSRI medication alone or in combination with clonazepam were studied from June 1996 through June 2000 and compared with a nonexposed control group (N = 23). Infants were assessed in the newborn period for signs suggestive of a "discontinuation syndrome." Maternal drug levels were measured during the pregnancy and at delivery. Infant drug levels from cord blood and at day 2 of life were also obtained. RESULTS: Overall, 30% of the exposed infants (groups 1 and 2, N = 14) showed symptoms of transient poor neonatal adaptation compared with 9% (N = 2) of control infants. In group 1, 25% had symptoms (fluoxetine N = 3; paroxetine N = 3; sertraline N = 1) and in group 2, 39% of infants had symptoms (paroxetine with clonazepam, N = 7). Symptoms were typically mild respiratory distress and, less commonly, hypotonia. Symptoms were self limited and not associated with other neonatal conditions. When paroxetine was combined with clonazepam, infants with symptoms had significantly elevated paroxetine levels when compared with similarly exposed infants without symptoms (p <.05). Among single-agent paroxetine-exposed infants, drug levels did not differ significantly between those with and without symptoms. Maternal dose of clonazepam was significantly higher (p <.05) during pregnancy and at delivery among symptomatic infants compared with nonsymptomatic infants. Developmental outcomes at 2 and 8 months of age did not differ between symptomatic and nonsymptomatic infants. CONCLUSION: While transient neonatal symptoms were found in infants after single-agent prenatal exposure to SSRIs and when paroxetine was combined with clonazepam, the addition of clonazepam appeared to alter paroxetine metabolism, leading to increased drug levels and risk for transient neonatal symptoms. These data highlight the importance of accounting for a variety of pharmacologic factors beyond single-agent SSRI exposure that may lead to poor neonatal adaptation. Further studies are needed with a larger sample of infants to determine the role of clonazepam and whether similar outcomes occur when exposure includes other SSRIs in combination with clonazepam.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Oberlander, T. F., Weinberg, J., Papsdorf, M., Grunau, R., Misri, S., & Devlin, A. M. (2008) · Epigenetics · doi:10.4161/epi.3.2.6034 · Cited by 1,432
Self-citationCohen, L. S. (2006) · JAMA · doi:10.1001/jama.295.5.499 · Cited by 1,031
Oberlander, T. F., Warburton, W., Misri, S., Aghajanian, J., & Hertzman, C. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.898 · Cited by 551
Self-citationMoses-Kolko, E. L., Bogen, D., Perel, J., Bregar, A., Uhl, K., Levin, B., & Wisner, K. L. (2005) · JAMA · doi:10.1001/jama.293.19.2372 · Cited by 533
Yonkers, K. A., Wisner, K. L., Stewart, D. E., Oberlander, T. F., Dell, D. L., Stotland, N., Ramin, S., Chaudron, L., & Lockwood, C. (2009) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2009.04.003 · Cited by 469
Self-citation(2009) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3181ba0632 · Cited by 345
Levinson-Castiel, R., Merlob, P., Linder, N., Sirota, L., & Klinger, G. (2006) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.160.2.173 · Cited by 329
Brummelte, S., Mc Glanaghy, E., Bonnin, A., & Oberlander, T. F. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2016.02.037 · Cited by 306
Self-citationInternalizing Behaviors in 4-Year-Old Children Exposed in Utero to Psychotropic Medications
Misri, S., Reebye, P., Kendrick, K., Carter, D., Ryan, D., Grunau, R. E., & Oberlander, T. F. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.6.1026 · Cited by 207
Self-citationOberlander, T. F., Reebye, P., Misri, S., Papsdorf, M., Kim, J., & Grunau, R. E. (2007) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.161.1.22 · Cited by 198
Self-citationLattimore, K. A., Donn, S. M., Kaciroti, N., Kemper, A. R., Neal, C. R., & Vazquez, D. M. (2005) · Journal of Perinatology · doi:10.1038/sj.jp.7211352 · Cited by 189
“Table 3 shows the results of the meta-analysis and lists the odds ratios (OR) and 95% confidence intervals (CI) for neonatal factors significantly impacted by in utero exposure to SSRIs.”
BackgroundResultInfluentialAntidepressant use in pregnancy: a critical review focused on risks and controversies
Byatt, N., Deligiannidis, K. M., & Freeman, M. P. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12042 · Cited by 158
“found that thirty per cent of infants exposed to SSRI alone or in combination with clonazepam showed symptoms of poor neonatal adaptation, 25% and 39%, respectively (104).”
BackgroundInfluentialSelective Serotonin Reuptake Inhibitor Exposure In Utero and Pregnancy Outcomes
Lund, N., Pedersen, L. H., & Henriksen, T. B. (2009) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpediatrics.2009.164 · Cited by 153
Review: problems associated with long-term treatment with selective serotonin reuptake inhibitors
Moret, C., Isaac, M., & Briley, M. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108093582 · Cited by 135
Antidepressants in pregnancy: a systematic review.
(2010) · PubMed · doi:10.3109/00048674.2010.507543 · Cited by 128
“, 2004 [10] Prospective cohort SSRIs n 28 SSRIs plus clonazepam n 18 Controls n 23 Exposed 38.”
BackgroundInfluentialBenzodiazepine exposure in pregnancy and risk of major malformations: a critical overview
Bellantuono, C., Tofani, S., Di Sciascio, G., & Santone, G. (2013) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2012.09.003 · Cited by 122
Prenatal exposure to antidepressant medications and neurodevelopmental outcomes: A systematic review
Gentile, S., & Galbally, M. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.02.125 · Cited by 123
The use of psychotropic medication during pregnancy: how about the newborn?
Kieviet, N., Honig, & Dolman (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s36394 · Cited by 100
Tuccori, M., Testi, A., Antonioli, L., Fornai, M., Montagnani, S., Ghisu, N., Colucci, R., Corona, T., Blandizzi, C., & Tacca, M. D. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.07.009 · Cited by 95
El Marroun, H., White, T., Verhulst, F. C., & Tiemeier, H. (2014) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-014-0558-3 · Cited by 92
Neurodevelopmental effects of prenatal exposure to psychotropic medications
Gentile, S. (2010) · Depression and Anxiety · doi:10.1002/da.20706 · Cited by 76
Sheffield, K. M., & Woods-Giscombé, C. L. (2016) · Journal of Holistic Nursing · doi:10.1177/0898010115577976 · Cited by 65
The effect of perinatal exposures on the infant: Antidepressants and depression
Hanley, G. E., & Oberlander, T. F. (2014) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2013.09.001 · Cited by 56
Self-citationPrenatal SSRI exposure: Effects on later child development
Hermansen, T. K., & Melinder, A. (2015) · Child Neuropsychology · doi:10.1080/09297049.2014.942727 · Cited by 38
Convertino, I., Sansone, A. C., Marino, A., Galiulo, M. T., Mantarro, S., Antonioli, L., Fornai, M., Blandizzi, C., & Tuccori, M. (2016) · Drug Safety · doi:10.1007/s40264-016-0435-8 · Cited by 32
Eleftheriou, G., Zandonella Callegher, R., Butera, R., De Santis, M., Cavaliere, A. F., Vecchio, S., Pistelli, A., Mangili, G., Bondi, E., Somaini, L., et al. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20166565 · Cited by 17
Metadata
- Authors
- Oberlander, T. F., Misri, S., Fitzgerald, C. E., Kostaras, X., Rurak, D., & Riggs, W.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2004-02-15
- Volume
- 65
- Issue
- 2
- Pages
- 230-237
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2069358062
- Cited by
- 244
- References
- 0
- FWCI
- 16.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.